November 21st 2024
In the recent news release, Koelis reported that the final patient was enrolled in the VIOLETTE study in September 2024.
November 13th 2024
AUA 2013: AUA guide takes tailored approach to PCa screening
May 4th 2013The AUA has released a PSA-focused, evidence-based guideline on early detection of prostate cancer that is intended to assist the urologist in advising an average-risk, asymptomatic man about prostate cancer screening, said H. Ballentine Carter, MD.
Anterior sampling may be safe alternative for prostate biopsy
April 23rd 2013Transrectal anterior zone sampling of the prostate may be a viable alternative to transperineal template biopsies in patients with negative previous biopsies and with rising PSA or persistently elevated PSA, researchers from the United Kingdom report.
Prostate cancer active surveillance criteria may need to be stratified by race
April 23rd 2013African-American men eligible for active surveillance have a higher risk of advanced cancer on final surgical pathology compared to Caucasian men, suggesting the need for more stringent criteria for active surveillance for African-American men, according to a recently published study.
FDA accepts HIFU maker’s pre-market application
April 22nd 2013EDAP TMS said the FDA has provided a positive filing review notification on the company’s pre-market approval application for its Ablatherm Integrated Imaging HIFU (high-intensity focused ultrasound) device for the treatment of low-risk, localized prostate cancer.
PSA screening cuts prostate cancer deaths by 32%, ERSPC data indicate
April 19th 2013New evidence from the second-largest section of the European Randomized Study of Screening for Prostate Cancer (ERSPC) suggests that prostate cancer screening is beneficial, particularly in the core age group of 55 to 69 years.
Diabetes, prostate cancer link: Surprising, or not?
April 17th 2013Men with abnormal findings on digital rectal exam or other indicators of prostate cancer should be tested, but the evidence is insufficient to justify preferentially screening diabetic men because they may be at a higher risk of developing clinically significant prostate cancer.
5-ARI does not affect prostate cancer mortality
April 2nd 2013Eighteen years of follow-up of the Prostate Cancer Prevention Trial (PCPT) suggests that 7 years of treatment with the 5-alpha-reductase inhibitor finasteride (Proscar) for prostate cancer prevention does not appear to affect mortality but does reduce the risk of a prostate cancer diagnosis.
Advanced prostate cancer agent efficacious regardless of age
April 2nd 2013Older men with metastatic castration-resistant prostate cancer (CRPC) derive a similar if not superior survival benefit from treatment with enzalutamide (Xtandi) as do younger men, according to a post-hoc analysis of the phase III AFFIRM trial.
Baldness raises PCa risk in African-Americans
March 26th 2013Baldness was associated with an increased risk of prostate cancer among African-American men, and risk for advanced prostate cancer increased with younger age and type of baldness, reported researchers from the University of Pennsylvania, Philadelphia.